RefleXion Medical IPO

RefleXion is a developer of a biology-guided radiotherapy system that aims to create a significant change in strategy from single tumor therapy to the ability to treat multiple tumors in the same treatment session in cancers that have metastasized. The company’s SCINTIX® technology has a mission of tracking period tumor and non-tumor motion to reach its goal of creating a dual treatment modality. RefleXion was founded by Akshay Nanduri and Sam Mazin in 2009 and is headquartered in Hayward, CA.

Register for Details

For more details on financing and valuation for RefleXion Medical, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about RefleXion Medical

To invest in RefleXion Medical pre-IPO

Can you invest in RefleXion Medical pre-IPO?

RefleXion Medical is a privately held company and is not publicly traded, therefore investing in RefleXion Medical pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can learn more about Forge’s Secondary Marketplace and how to invest in private companies before their potential IPO. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

Can you sell shares of RefleXion Medical before it goes public?

You can seek to sell your shares in RefleXion Medical while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

What is the pre-IPO value of my RefleXion Medical shares?

To determine the value of your RefleXion Medical shares, create a free account to gain access to Forge’s platform. In addition to the Forge Price, Forge Markets contains pricing information for hundreds of pre-IPO companies such as Last Closed Trade Price. A Private Market Specialist will also be available to assist you with any inquiries related to your RefleXion Medical shares. You can also learn more about how to sell your private shares before getting started.

Is RefleXion Medical a publicly traded company?

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

To learn more about RefleXion Medical potential IPO

Will RefleXion Medical go IPO?

RefleXion Medical has not yet filed for an IPO. However, it’s important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

What is RefleXion Medical’s IPO price?

The RefleXion Medical IPO price does not exist at this time, as RefleXion Medical is still a private company and has not yet conducted an IPO. To explore secondary market data and access private market pricing details and data that may be related to RefleXion Medical register for Forge Markets, today.

When was RefleXion Medical founded?

RefleXion Medical was founded in 2009.

What is RefleXion Medical funding to date?

RefleXion Medical has raised $957.66MM to date.

Who are RefleXion Medical’s major investors?

Sofinnova Partners
Tpg
Ally Bridge Group
Catalio Capital Management
The Rise Fund
Pfizer Venture Investments
Catalio
Ally Bridge
Hillenbrand Capital Partners
Sixty Degree Capital
Kck Group
Pimlico Pond Investments
T. Rowe Price
Pfizer Ventures Investments
Inspovation Ventures
Pfizer Ventures
Gt Healthcare Capital Partners
Ascension Ventures
Hillenbrand
Johnson & Johnson Innovation
Pictet
Pfizer Venture
Venrock
Psp Investments
T.Rowe Price Associates
Square Point Capital
National Institutes Of Health
T. Rowe Price Associates
U.S. Department Of Health & Human Services

RefleXion Medical Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
11/15/2023 Series F $32.74MM $xx.xx $1.34B The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
Price per Share
$xx.xx
Shares Outstanding
21,839,817
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
11/15/2023 Series E-X $18.01MM $xx.xx $1.34B The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
Price per Share
$xx.xx
Shares Outstanding
7,597,170
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.4x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
11/15/2023 Series D-X $20.47MM $xx.xx $1.34B The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
Price per Share
$xx.xx
Shares Outstanding
10,734,817
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
11/15/2023 Series D-1-X $6.55MM $xx.xx $1.34B The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
Price per Share
$xx.xx
Shares Outstanding
2,872,489
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.4x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
11/15/2023 Series C-X $16.8MM $xx.xx $1.34B The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
Price per Share
$xx.xx
Shares Outstanding
9,928,010
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
11/15/2023 Series B-X $8.51MM $xx.xx $1.34B The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
Price per Share
$xx.xx
Shares Outstanding
7,891,388
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
11/15/2023 Series A-X $1.92MM $xx.xx $1.34B The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
Price per Share
$xx.xx
Shares Outstanding
5,583,233
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
03/10/2022 Series E $110MM $xx.xx $785.79MM Ascension Ventures, Catalio Capital Management, Sixty Degree Capital, Hillenbrand Capital Partners, The Rise Fund, KCK Group, PSP Investments, T. Rowe Price, Ally Bridge Group, Venrock, Pfizer Ventures Investments, Johnson & Johnson Innovation
Price per Share
$xx.xx
Shares Outstanding
46,402,813
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.4x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Ascension Ventures, Catalio Capital Management, Sixty Degree Capital, Hillenbrand Capital Partners, The Rise Fund, KCK Group, PSP Investments, T. Rowe Price, Ally Bridge Group, Venrock, Pfizer Ventures Investments, Johnson & Johnson Innovation
03/02/2021 Series D-1 $40MM $xx.xx $650.69MM Ally Bridge Group
Price per Share
$xx.xx
Shares Outstanding
17,544,898
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.4x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Ally Bridge Group
04/16/2020 Series D $125MM $xx.xx $496.89MM The Rise Fund, T. Rowe Price Associates, GT Healthcare Capital Partners, Sofinnova Partners, KCK Group, Venrock, Pfizer Venture Investments, Johnson & Johnson Innovation
Price per Share
$xx.xx
Shares Outstanding
65,567,269
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
The Rise Fund, T. Rowe Price Associates, GT Healthcare Capital Partners, Sofinnova Partners, KCK Group, Venrock, Pfizer Venture Investments, Johnson & Johnson Innovation
04/04/2018 Series C $102.6MM $xx.xx $322.47MM The Rise Fund, T. Rowe Price Associates, GT Healthcare Capital Partners, Sofinnova Partners, KCK Group, Venrock, Pfizer Venture Investments, Johnson & Johnson Innovation
Price per Share
$xx.xx
Shares Outstanding
60,639,366
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
The Rise Fund, T. Rowe Price Associates, GT Healthcare Capital Partners, Sofinnova Partners, KCK Group, Venrock, Pfizer Venture Investments, Johnson & Johnson Innovation
07/19/2016 Series B $52MM $xx.xx $118.39MM KCK Group, Venrock, Pfizer Venture Investments, Sofinnova Partners, Johnson & Johnson Innovation
Price per Share
$xx.xx
Shares Outstanding
48,199,870
Liquidation Pref Order
6
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
KCK Group, Venrock, Pfizer Venture Investments, Sofinnova Partners, Johnson & Johnson Innovation
04/04/2014 Series A $11.73MM $xx.xx $19.55MM Sofinnova Partners, Pfizer Venture, Venrock
Price per Share
$xx.xx
Shares Outstanding
34,101,874
Liquidation Pref Order
7
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Sofinnova Partners, Pfizer Venture, Venrock
Updated on: Nov 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.